Telix Pharmaceuticals Equity 2024

Telix Pharmaceuticals Aktienanalyse

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Telix Pharmaceuticals's Equity

Telix Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Telix Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Telix Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Telix Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Telix Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Telix Pharmaceuticals stock

What is the equity of Telix Pharmaceuticals this year?

Telix Pharmaceuticals has equity of 148.91 M AUD this year.

What was the equity of Telix Pharmaceuticals compared to the previous year?

The equity of Telix Pharmaceuticals has increased/decreased by 86.12% increased compared to the previous year.

What impact does a high equity have on investors of Telix Pharmaceuticals?

A high equity is advantageous for investors of Telix Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Telix Pharmaceuticals?

A low equity can be a risk for investors of Telix Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Telix Pharmaceuticals affect the company?

An increase in equity of Telix Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Telix Pharmaceuticals affect the company?

A reduction in equity of Telix Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Telix Pharmaceuticals?

Some factors that can affect the equity of Telix Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Telix Pharmaceuticals so important for investors?

The equity of Telix Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Telix Pharmaceuticals take to change the equity?

To change equity, Telix Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Telix Pharmaceuticals pay?

Over the past 12 months, Telix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Telix Pharmaceuticals?

The current dividend yield of Telix Pharmaceuticals is .

When does Telix Pharmaceuticals pay dividends?

Telix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Telix Pharmaceuticals?

Telix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Telix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Telix Pharmaceuticals located?

Telix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Telix Pharmaceuticals from 9/30/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Telix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Telix Pharmaceuticals in the year 2023?

In the year 2023, Telix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Telix Pharmaceuticals pay out the dividend?

The dividends of Telix Pharmaceuticals are distributed in AUD.